Immunovaccine Appoints Marc Mansour as Chief Executive Officer
June 11 2014 - 8:18AM
Marketwired
Immunovaccine Appoints Marc Mansour as Chief Executive Officer
HALIFAX, NOVA SCOTIA--(Marketwired - Jun 11, 2014) -
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company")
(TSX-VENTURE:IMV), a clinical stage vaccine and immunotherapy
company, today announced that Marc Mansour, Ph.D., MBA, has been
appointed Chief Executive Officer. Albert Scardino, executive
chairman since last year, will return to his role as non-executive
chairman of the Company. Dr. Mansour has previously served as the
Company's Chief Operating Officer and Chief Science Officer and is
a member of its board of directors.
Since joining Immunovaccine in 2001, Dr. Mansour has led the
development of Immunovaccine's DepoVax™ platform and the Company's
lead therapeutic cancer vaccine DPX-Survivac, which is being
prepared for multiple Phase II clinical studies in 2014. During his
recent tenure as COO, Dr. Mansour also spearheaded interactions
with the investment community, as well as business development
efforts.
Albert Scardino, chairman of Immunovaccine, commented,
"During his 13 years at Immunovaccine, Marc has contributed to
all aspects of our development, from cutting-edge scientific
research to day-to-day corporate operations. No individual has a
better understanding of where Immunovaccine has been or what it
will take to advance the Company to the next phase of its
evolution."
Immunovaccine earlier this month presented positive results from
a Phase I/Ib clinical study of DPX-Survivac at the American Society
of Clinical Oncology (ASCO) 2014 Annual Meeting, demonstrating the
first evidence of clinical activity for the cancer vaccine.
While the majority of ovarian cancer patients enrolled in the
study were complete responders to their previous therapy and
presented no evidence of disease at the time of enrollment, three
patients entered the Phase Ib study with stable disease. One of
those three patients experienced a partial response (PR) as
measured by Response Evaluation Criteria In Solid Tumors (RECIST
1.1), while the other two experienced disease progression. The
responding patient achieved a 43% reduction in tumor size, as well
as reduction in levels of a commonly used ovarian cancer biomarker
(CA125) and a significant increase in vaccine-induced immune
responses. The patient's tumor and CA125 levels remain stable eight
months following initiation of the DPX-Survivac therapy,
demonstrating a potentially durable effect of the therapy.
"This is an exciting time for Immunovaccine and the broader
cancer immunotherapy field. Our announcement of the DPX-Survivac
data at the annual ASCO conference has resulted in a significant
amount of interest from key opinion leaders for further
investigation of the cancer vaccine. As a direct result of this KOL
interest, we are exploring two additional Phase II clinical studies
of DPX-Survivac in ovarian cancer and lymphoma potentially in
2014," stated Dr. Mansour.
As previously announced, a large randomized Phase II trial of
DPX-Survivac in ovarian cancer will be sponsored and conducted by
Canada's NCIC Clinical Trials Group (NCIC CTG). The NCIC CTG is
expected to initiate the 250 patient trial in 2014.
About Immunovaccine
Immunovaccine Inc. develops cancer immunotherapies and
infectious disease vaccines based on the Company's DepoVax™
platform, a patented formulation that provides controlled and
prolonged exposure of antigens and adjuvant to the immune system.
Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine
therapy, DPX-Survivac, is expected to enter Phase II clinical
studies in both ovarian cancer and glioblastoma (brain cancer). The
Company is also advancing an infectious disease pipeline including
innovative vaccines for respiratory syncytial virus (RSV) and
anthrax.
Connect at www.imvaccine.com
This press release contains forward-looking information
under applicable securities law. All information that addresses
activities or developments that we expect to occur in the future,
including information regarding the use of proceeds of the
financing, is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on
the date the statements are made. However, they should not be
regarded as a representation that any of the plans will be
achieved. Actual results may differ materially from those set forth
in this press release due to risks affecting the company, including
access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Immunovaccine Inc.Dr. Marc MansourChief Executive Officer(902)
492-1819mmansour@imvaccine.comwww.imvaccine.comVida Strategic
Partners (media)Tim Brons(415) 675-7402tbrons@vidasp.com
(TSXV:IMV)
Historical Stock Chart
From Sep 2024 to Oct 2024
(TSXV:IMV)
Historical Stock Chart
From Oct 2023 to Oct 2024